What is Northland Securities’ Estimate for TLSI Q1 Earnings?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Investment analysts at Northland Securities lowered their Q1 2026 EPS estimates for shares of TriSalus Life Sciences in a research note issued on Monday, March 23rd. Northland Securities analyst C. Byrnes now expects that the company will post earnings of ($0.16) per share for the quarter, down from their prior forecast of ($0.12). The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share. Northland Securities also issued estimates for TriSalus Life Sciences’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.45) EPS and FY2027 earnings at ($0.25) EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to the consensus estimate of $13.20 million.

TLSI has been the topic of a number of other reports. Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Finally, Canaccord Genuity Group lowered their price target on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, March 6th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $7.00.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI opened at $4.01 on Wednesday. The stock has a 50-day simple moving average of $4.80 and a two-hundred day simple moving average of $5.27. The firm has a market capitalization of $245.84 million, a PE ratio of -2.19 and a beta of 0.42. TriSalus Life Sciences has a 52-week low of $3.42 and a 52-week high of $7.95.

Insider Activity

In related news, CEO Mary T. Szela sold 15,944 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.85, for a total transaction of $61,384.40. Following the sale, the chief executive officer owned 752,987 shares of the company’s stock, valued at $2,898,999.95. This represents a 2.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 30,150 shares of company stock worth $119,849. 27.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors have recently modified their holdings of the stock. Invesco Ltd. purchased a new stake in TriSalus Life Sciences in the 4th quarter worth about $72,000. Man Group plc purchased a new position in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $102,000. Abel Hall LLC purchased a new position in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $73,000. Kotler Kevin bought a new position in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $1,013,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of TriSalus Life Sciences in the fourth quarter worth approximately $104,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences News Summary

Here are the key news stories impacting TriSalus Life Sciences this week:

• Neutral Sentiment: Short‑interest reports show 0 shares short and a 0.0 days‑to‑cover figure for March 24 — language in the filings indicates anomalous/empty data rather than a meaningful build of short positions. This item is unlikely to be a real bullish or bearish driver. MarketBeat TLSI short interest
• Negative Sentiment: Northland Securities (analyst C. Byrnes) cut EPS forecasts across 2026–2027: Q1 2026 to ($0.16) from ($0.12); Q2 to ($0.11) from ($0.09); Q3 to ($0.10) from ($0.08); Q4 to ($0.09) from ($0.07); FY2026 to ($0.45) from ($0.35); FY2027 to ($0.25) from ($0.20). These downgrades lower near‑term profitability expectations and are a headwind for the stock. Northland Securities estimate changes

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.